Paid Clinical Trials Mobile

Discover 193 paid clinical trials in Mobile, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 193

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Pensacola FL, Gulf Breeze FL, Flowood MS, Ridgeland MSshow 41 more

Code:

NCT04616326

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Galcanezumab

Placebo

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Pensacola FL, Ridgeland MS, Baton Rouge LA, Fayette MSshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Pensacola FL, New Orleans LA, Jackson MS, Birmingham ALshow 103 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaA Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Mobile AL, New Orleans LA, Tallahassee FL, Lafayette LAshow 62 more

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Mobile AL, Thomasville GA, Monroe LA, Shreveport LAshow 29 more

Code:

NCT06393374

Conditions

Triple-Negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Sacituzumab tirumotecan

Capecitabine

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Recruiting

PHASE3

Sponsor:

Ferring Pharmaceuticals

Location:

Mobile AL, Creve Coeur MO, Myrtle Beach SC, Virginia Beach VAshow 7 more

Code:

NCT06510374

Conditions

Intermediate Risk Non-Muscle Invasive Bladder Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nadofaragene Firadenovec

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Fairhope AL, Macon GA, Atlanta GA, Conyers GAshow 126 more

Code:

NCT06268873

Conditions

Chronic Kidney Disease and Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Baxdrostat/dapagliflozin

Dapagliflozin in combination with placebo

NICU Antibiotics and Outcomes TrialNICU Antibiotics and Outcomes Trial

Recruiting

Sponsor:

Michael Morowitz

Location:

Mobile AL, Tampa FL, Louisville KY, Winston-Salem NCshow 13 more

Code:

NCT03997266

Conditions

Microbial Colonization

Extreme Prematurity

Early-Onset Neonatal Sepsis

Late-Onset Neonatal Sepsis

Necrotizing Enterocolitis of Newborn

Eligibility Criteria

Sex: All

Age: 0 - 4

Healthy Volunteers: Not accepted

Interventions

Ampicillin

Gentamycin

Normal saline

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Mobile AL, Fairhope AL, Gulfport MS, Zachary LAshow 196 more

Code:

NCT06283966

Conditions

COPD (Chronic Obstructive Pulmonary Disease)

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

BGF MDI 320/14.4/9.6 μg

GFF MDI 14.4/9.6 μg

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's SarcomaCombination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Recruiting

PHASE3

Sponsor:

University of Leicester

Location:

Pensacola FL, New Orleans LA, Jackson MS, Birmingham ALshow 88 more

Code:

NCT00020566

Conditions

Sarcoma

Eligibility Criteria

Sex: All

Age: 0 - 49

Healthy Volunteers: Not accepted

Interventions

dactinomycin

busulfan

doxorubicin hydrochloride

etoposide

ifosfamide